Research Article

In Vitro and In Vivo Transdermal Delivery of Rivastigmine via Ethosomal Gel Formulations for the Treatment of Alzheimer's Disease

119 reads
SCI J Pharm Pharm Sci, 2026, 1 (1), 15-21, ISSN

Abstract

Rivastigmine hydrogen tartrate is a dual cholinesterase inhibitor widely utilized for the symptomatic management of mild-to-moderate Alzheimer's disease. However, its oral administration is severely limited by short biological half-life, extensive first-pass hepatic metabolism, and pronounced gastrointestinal side effects. Transdermal drug delivery systems offer a promising strategy to overcome these drawbacks, yet the stratum corneum barrier impedes effective cutaneous absorption of hydrophilic molecules. In this study, novel ethosomal gel formulations were developed and evaluated for enhanced transdermal delivery of rivastigmine. Ethosomes composed of soya phosphatidylcholine and ethanol were prepared using the cold method, optimized for vesicle size, entrapment efficiency, and zeta potential, and subsequently incorporated into a Carbopol 934 gel matrix (E-Gel). Ex vivo skin permeation studies using excised rat skin demonstrated that the optimized ethosomal gel exhibited a significantly higher cumulative drug permeation flux (48.52 ± 3.12 µg/cm²/h) compared to conventional hydrogel and commercial patch controls. In vivo pharmacokinetic assessment in Wistar rats revealed a 2.8-fold increase in systemic bioavailability (AUC0-∞) and sustained plasma concentration over 24 hours. Furthermore, in vivo pharmacodynamic evaluation using the Morris water maze in a scopolamine-induced amnesia model confirmed marked cognitive enhancement and significant restoration of brain acetylcholinesterase activity. These results indicate that ethosomal gel represents an advanced dermal platform for sustained transdermal rivastigmine delivery in Alzheimer's therapy.

Keywords pharmacokinetics alzheimer's disease transdermal drug delivery Rivastigmine Ethosomal gel
Authors 3

The team behind this paper

3 authors, 3 institutions.

This paper Charles University Charles University 1 author Kyoto University — Japan Kyoto University 1 author University of Ibadan — Nigeria University of Ibadan 1 author Prof. Elena Rostova — corresponding author ER Prof. Elena Rostova ✉ Dr. Hiroshi Tanaka HT Dr. Hiroshi Tanaka Dr. Amara Nwosu AN Dr. Amara Nwosu

Readership

119 reads over 4 months.

#2 most read in this journal this month
August 2026 November 2026

Bibliographic Information

Prof. Elena Rostova, Dr. Hiroshi Tanaka, Dr. Amara Nwosu, (2026). In Vitro and In Vivo Transdermal Delivery of Rivastigmine via Ethosomal Gel Formulations for the Treatment of Alzheimer's Disease, SCI Journal of Pharmacy and Pharmaceutical Sciences, 1(1): 15-21
Bibtex Citation
@article{prof._elena_rostova2026sjpps,
author = {Prof. Elena Rostova and Dr. Hiroshi Tanaka and Dr. Amara Nwosu},
title = {In Vitro and In Vivo Transdermal Delivery of Rivastigmine via Ethosomal Gel Formulations for the Treatment of Alzheimer's Disease},
journal = {SCI Journal of Pharmacy and Pharmaceutical Sciences},
year = {2026},
volume = {1},
number = {1},
pages = {15-21},
doi = {},
url = {https://scimatic.org/show_manuscript/8950}
}
APA Citation
Rostova, P.E., Tanaka, D.H., Nwosu, D.A., (2026). In Vitro and In Vivo Transdermal Delivery of Rivastigmine via Ethosomal Gel Formulations for the Treatment of Alzheimer's Disease. SCI Journal of Pharmacy and Pharmaceutical Sciences, 1(1), 15-21. https://doi.org/

Author Information

  • To change your profile photo, login to scimatic.org, go to your profile and change the photo.
  • Any photo that shows your face will do: we crop it to your head and shoulders and give it a plain background automatically.
  • To sign in, go to Sign in and enter the e-mail address registered with the article: we e-mail you a one-time sign-in link (there is no password).
  • In case of any other problem, contact your editor directly or write to us at info @ scimatic.org